These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14968900)

  • 21. Adrenoceptor agonist poisoning after accidental oral ingestion of brimonidine eye drops.
    Hoffmann U; Kuno S; Franke G; Fusch C; Haas JP
    Pediatr Crit Care Med; 2004 May; 5(3):282-5. PubMed ID: 15115569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma.
    Walters G; Taylor RH
    Eye (Lond); 1999 Dec; 13 ( Pt 6)():797-8. PubMed ID: 10707152
    [No Abstract]   [Full Text] [Related]  

  • 23. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
    Shi JM; Jiang YQ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ophthalmic drops causing coma in an infant.
    Berlin RJ; Lee UT; Samples JR; Rich LF; Tang-Liu DD; Sing KA; Steiner RD
    J Pediatr; 2001 Mar; 138(3):441-3. PubMed ID: 11241061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
    Lee JS; Kim CY
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anterior uveitis and topical brimonidine: a case report].
    Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
    J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?
    Kiryazov K; Stefova M; Iotova V
    Pediatr Emerg Care; 2013 Nov; 29(11):1207-9. PubMed ID: 24196091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study.
    Abdulrazik M; Tamilvanan S; Benita S
    J Drug Target; 2006 Dec; 14(10):670-9. PubMed ID: 17162736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy.
    Danylkova NO; Alcala SR; Pomeranz HD; McLoon LK
    Exp Eye Res; 2007 Feb; 84(2):293-301. PubMed ID: 17113077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic brimonidine before LASIK.
    Uretmen O; Ates H; Andaç K
    J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma.
    Gill K; Bayart C; Desai R; Golden A; Raimer P; Tamburro J
    Pediatr Dermatol; 2016 Jul; 33(4):e232-4. PubMed ID: 27282306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
    Ma YR; Lee BH; Yang KJ; Park YG
    Korean J Ophthalmol; 1999 Dec; 13(2):78-84. PubMed ID: 10761402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting.
    Weigert G; Resch H; Garhofer G; Fuchsjäger-Mayrl G; Schmetterer L
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4220-5. PubMed ID: 17724210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.